Health Care/Hospital
Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI
CAMBRIDGE, Mass., April 22, 2026 /PRNewswire/ -- Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 protein-coding genes, only about 4,500 are considered "druggable," and notably, all approved drug...
2026-04-22 21:00
3548
Manulife and the World Economic Forum's UpLink Initiative Launch Canadian Longevity Innovation Challenge
'Shaping Canada's Longevity Advantage' challenge will invite innovators to deliver solutions that strengthen health, financial resilience and social connection across longer lives The challenge is an initiative of Manulife's Longevity Institute, driving Canadian solutions for a longer‑living soc...
2026-04-22 20:00
3472
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
SHANGHAI, April 22, 2026 /PRNewswire/ -- Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative dr...
2026-04-22 17:40
3855
Hong Kong Life Celebrates Its 25th Anniversary Under the Theme "Hong Kong Life 25 Years With You" Launching a Series of Brand Campaigns and Exclusive Rewards
HONG KONG, April 22, 2026 /PRNewswire/ -- Established in 2001, Hong Kong Life Insurance Limited ("Hong Kong Life") has been serving the community for a quarter-century. Upholding the core values of being customer-centric and committed to continuous innovation, the Company strives to deliver high-...
2026-04-22 17:14
3524
Chulalongkorn University doctors successfully performed surgery for obstructive sleep apnea using the new HGNS technique the fourth successful surgery of this kind in Asia
BANGKOK, April 22, 2026 /PRNewswire/ -- The Excellence Center for Sleep
Disorders,King Chulalongkorn Memorial Hospital, Thai Red Cross Society
2026-04-22 14:54
3687
Samsung Biologics Reports First Quarter 2026 Financial Results
* Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion * Performance driven by full utilization across Plants 1 through 4 and robust operational execution * Strengthened the foundations for future growth through U.S. expansion and strategic partnerships INCHEO...
2026-04-22 14:50
3571
NEW TELE-DENTISTRY PROGRAMME SUPPORTS EARLY INTERVENTION FOR CHILDREN AT RISK OF CARIES
Targeting vulnerable families, the collaborative programme empowers parents with personalised insights and clear, prioritised guidance for their children's oral care SINGAPORE, April 22, 2026 /PRNewswire/ -- For many families, dental care decisions tend to be reactive, made only when a child exp...
2026-04-22 14:46
3032
AscendCare Medical Clinic Launches Public Awareness Initiative to Normalise Regular Health Screening in Singapore
SINGAPORE, April 22, 2026 /PRNewswire/ -- AscendCare Medical Clinic, a modern healthcare provider based in Tanjong Pagar, today announced a new public education initiative designed to reframe health screenings as a routine and responsible component of personal wellness. The campaign addresses a c...
2026-04-22 14:13
3573
ImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'
* ImmunoForge's LMT15 Platform combines high BBB permeability with proprietary long-acting ELP technology * Technology excellence validated by winning first place at 'Novo Nordisk Partnering Day Korea 2026' SEOUL, South Korea, April 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical...
2026-04-22 14:13
2463
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
SUZHOU, China, April 22, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with...
2026-04-22 14:10
1085
Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA
BEIJING, April 22, 2026 /PRNewswire/ -- Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results...
2026-04-22 11:09
2636
NOVI Health's Hybrid Care Model Closes Gap Between Clinical Trials and Real-World GLP-1 Outcomes
An estimated ~14.7% weight loss at 18 months was achieved in one of the first studies evaluating integrated GLP-1 therapies and digital coaching in a multi-ethnic Asian population (n=708). This matched gold-standard clinical trial results, with digital coaching acting as a measurable multiplier. ...
2026-04-22 11:00
3780
Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker reductions — — Preliminary data from 180 mg cohort shows trends of clinical stabilization (ALSFRS-R) — — Phase II trial is now actively dosing participants — CHICAGO, April 2...
2026-04-22 10:10
3707
Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
TOKYO, April 22, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D projects for the development of drugs for malaria and neglected tropical diseases (NTDs).2 Investment of a...
2026-04-22 10:00
3226
SynbioTech's L. plantarum FS4722 Emerges as a Potential Preventive Approach for Hyperuricemia
TAIPEI, April 22, 2026 /PRNewswire/ -- SynbioTech announced that its Lactiplantibacillus plantarum FS4722 (L. plantarum FS4722), a probiotic strain isolated from traditional Chinese pickled vegetables, has demonstrated potential to support urate regulation in hyperuricemia. L. plantarum FS4722 h...
2026-04-22 09:30
2881
Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, includi...
2026-04-22 08:59
4390
Dawn Medical Technologies Acquires Controlling Interest in Pinnacle Health in Vietnam
* Strategic entry into high-growth Vietnam market * Combines Dawn's product sourcing capabilities with Pinnacle Health's established local presence and market expertise * Advances Dawn's mission to expand access to high-quality, affordable medical technologies across Southeast Asia SINGAPORE...
2026-04-22 08:00
4286
Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
SHANGHAI, April 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment ...
2026-04-22 08:00
4635
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China, April 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2026-04-22 08:00
3609
ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026
Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting SEOUL, South Korea, April 21, 2026 /PRNewswire/ -- ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that resu...
2026-04-22 07:30
2842
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
6234
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
6218
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6021
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5951
